Twist Bioscience (TWST) EBT Margin (2017 - 2026)

Twist Bioscience has disclosed EBT Margin across 10 years of filings, most recently posting 39.72% for Q1 2026.

• In Q1 2026, EBT Margin rose 247.0% year-over-year to 39.72%; the TTM figure through Mar 2026 stood at 19.67% (up 3521.0% YoY), while the FY2025 annual figure was 20.43%, up 4608.0% from the prior year.
• EBT Margin eased to 39.72% in Q1 2026, from 29.18% in the prior quarter.
• Over the last five years, EBT Margin for TWST reached as high as 21.43% in Q2 2025 and fell as low as 126.37% in Q1 2022.
• The 5-year median for EBT Margin is 59.98% (2023), against an average of 63.17%.
• Annual changes were most pronounced in 2024 — EBT Margin sank 1574 bps — and 2025, when it jumped 12623 bps.
• A 5-year view of EBT Margin shows it stood at 76.96% in 2022, then advanced by 22 bps to 59.98% in 2023, then soared by 41 bps to 35.5% in 2024, then rose by 18 bps to 29.18% in 2025, then plunged by 36 bps to 39.72% in 2026.
• According to Business Quant data, EBT Margin over the past three periods registered 39.72%, 29.18%, and 27.15% for Q1 2026, Q4 2025, and Q3 2025 respectively.